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Abstract
Background: Chronic prostatitis otherwise known as chronic pelvic pain syndrome is a common urological
diagnosis that causes many men significant morbidity and has a detrimental effect on their quality of life. Standard
treatment with antibiotics and simple analgesia are often ineffective and many patients are managed by the
chronic pain services.
Cognitive behavioural therapy has been shown to be helpful in the management of many chronic diseases and
has recently been proposed as an effective treatment for chronic prostatitis. Furthermore, a self management
programme administered to groups of men with lower urinary tract symptoms has been shown to be more
effective than standard treatments including surgery.
Therefore, we have developed a cognitive behavioural therapy programme specifically for men with chronic
prostatitis. This novel treatment approach will be compared to conventional therapy in the pain clinic such as
atypical analgesia and local anaesthetic injections in the context of a randomised controlled trial.
Methods/Design: Men will be recruited from general urology outpatient clinics following the exclusion of other
diagnoses that could be responsible for their symptoms. Men will be randomised to attend either a self
management healthcare and education programme or to pain clinic referral alone. The self management
programme will be administered by a clinical psychologist to small groups of men over six consecutive weekly
sessions each lasting two hours. Patients will be taught techniques of problem-solving and goal-setting and will
learn coping mechanisms and how to modify catastrophic cognition.
The primary outcome will be change from baseline in the National Institute of Health Chronic Prostatitis Symptom
Index, a validated instrument for the assessment of men with chronic prostatitis. Secondary outcomes include
generic quality of life scores and analgesic and drug usage. Outcomes will be assessed at 2, 6 and 12 months.
Discussion: If this group administered self management programme is shown to be effective in the treatment of
men with chronic prostatitis it may become the new standard of care for these patients. Furthermore, it may be
adapted for use in women with interstitial cystitis, a condition which is analogous to chronic prostatitis in men.
Trial Registration: Current Controlled Trials ISRCTN21012555
Background
Prostatitis is a common urological diagnosis in men of
all ages, representing 8% of male urology office visits
[1]. Type III prostatitis, also referred to as chronic pros-
tatitis/chronic pelvic pain syndrome (CP/CPPS) is the
most common type and accounts for 90-95% of prostati-
tis diagnoses [2].
Standard care for men with CP/CPPS has tradition-
ally consisted of initial assessment by a urological sur-
geon to exclude an underlying reversible organic cause
for pain, followed by a non-uniform pathway that
incorporates a variety of pharmacological approaches
including antibiotics, non-steroidal anti-inflammatory
drugs, alpha-adrenoceptor blockers, 5-alpha-reductase
inhibitors and specialist pain-clinic approaches such as
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approach is consistently beneficial underpins the fact
that the underlying condition is multifactorial in its
pathogenesis and includes physical, emotional and psy-
chological components [3]. Effective treatment, there-
fore, must focus not only on the physical pathology
but also the emotional and psychological aspects of the
disorder. Psychosocial factors were recently targeted in
the development of a cognitive-behavioural programme
designed specifically for men with CP/CPPS [4].
Furthermore, a recent analysis of the large National
I n s t i t u t eo fH e a l t hC h r o n i cP rostatitis Cohort showed
that psychological variables could predict pain experi-
ence [5].
Self management interventions that enhance patients’
problem solving and goal-setting skills have been shown
to be effective for a number of chronic diseases includ-
ing arthritis, diabetes and asthma through reduction in
secondary care referrals, reduced primary care atten-
dance and increased self efficacy [6]. More recently a
group-directed self management programme has been
shown to improve both symptoms and quality of life in
men with lower urinary tract symptoms attributed to
benign prostatic hyperplasia [7].
We have developed a programme of cognitive beha-
vioural therapy for men with CP/CPPS. This interven-
tion uses personal health planning and self directed care
delivered in the context of small group sessions. We
believe that through this holistic approach we can
improve these patients’ quality of life and functional sta-
tus, reduce their pain and reduce the need for sustained
primary and secondary care consultation.
The main objective of the study is to show that our
programme of group-directed cognitive behavioural
therapy for men with CP/CPPS is more effective than
standard therapy (pain relief and coping mechanisms
delivered in the pain clinic).
Methods/Design
Study Design
We believe that our self management programme would
be best evaluated in the context of a randomised con-
trolled trial compared to standard care. A randomised
controlled trial is the most rigorous trial design that will
allow comparison of the effectiveness of our interven-
tion with standard treatment and will also allow an eco-
nomic evaluation.
Setting
The trial will take place at the Norfolk and Norwich
University Hospital NHS Foundation Trust. The treat-
ment sessions will take place at the Pain Management
Centre and follow-up visits will be scheduled in the hos-
pital outpatient department.
Patients
We will recruit men with CP/CPPS that has not
responded to simple treatment with painkillers or anti-
biotics from general urology outpatient clinics at Nor-
folk and Norwich University Hospital NHS Foundation
T r u s t .A l lp a t i e n t sa g e d1 8o ro v e rw i t hC P / C P P S
referred for the first time by their GP will be eligible for
inclusion. All patients will be assessed by a consultant
urologist to diagnose CP/CPPS and exclude other
important causes for their symptoms (for example, ure-
teric stones, prostate cancer).
Patients meeting these inclusion criteria will be offered
the opportunity to take part in the study. Those who do
not wish to take part will be offered standard care and
be referred to the pain clinic if they wish.
If during the course of the study it becomes clear that
further psychological treatment would be required for
an unexpected diagnosis in a given participant, this
would be made available.
Vulnerable patients, those who are unable to consent
for themselves and patients who do not speak English
will be excluded from the study. A detailed and explicit
list of inclusion and exclusion criteria is provided in
Table 1.
Power Calculation
This is based on the primary outcome measure, the
National Institute of Health Chronic Prostatitis Symp-
tom Index (NIH-CPSI, see Figure 1). Mean NIH-CPSI
scores in published trials are around 25, with standard
deviation in the region 6-7. To detect a mean fall in
NIH-CPSI of 4 points, we used CPSI score in control of
25.2, and CPSI score of 21.2 in the intervention with
standard deviations of 6.1 and 7.2 in the control and
intervention respectively. At 90% power, 5% two sided
significance level, we estimate a sample size of 59 indivi-
duals in each group. Taking account of 15% loss to
Table 1 Inclusion and Exclusion Criteria
Inclusion Criteria
￿ Men
￿ Age 18 years or order
￿ Diagnosis of Type III chronic prostatitis/chronic pelvic pain
syndrome by a consultant urologist
￿ Failure of simple analgesia and antibiotics to control symptoms
Exclusion Criteria
￿ Prostate cancer or suspected prostate cancer
￿ Renal tract calculi
￿ Acute bacterial prostatitis
￿ Other urological and non-urological diagnoses that could account
for a patient’s symptoms
￿ Inability to comprehend and converse in the English language
￿ Vulnerable adults
A comprehensive list of the study inclusion and exclusion criteria.
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Page 2 of 7Figure 1 NIH-Chronic Prostatitis Symptom Index. The National Institutes of Health Chronic Prostatitis Symptom Index, a validated
questionnaire for the assessment of men with CP/CPPS. It evaluates pain and urinary symptoms, and assesses the impact of the condition on
function and quality of life.
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giving a total sample size of 120.
Randomisation methods
Randomisation will be carried out by a method of Ran-
dom Permuted Blocks so as to ensure exact equal treat-
ment numbers at certain equally spaced time points in
the sequence of patient assignments. The randomisation
sequence will be generated using statistical software in
random blocks, size of four individuals per block.
Assessment of outcome
The primary outcome will be change from baseline in
the NIH-CPSI, a validated instrument used for the
assessment of men with CP/CPPS (see Figure 1) [8].
The NIH-CPSI assesses domains of pain, urinary func-
tion, sexual function, and the impact of symptoms on
quality of life.
Secondary outcomes will include the SF-36, HAD
(Hospital Anxiety and Depression) scale and PAM
(Patient Activation Measurement) tool. The SF-36 will
provide a measure of generic quality of life. The HAD
scale is a self-screening questionnaire for depression and
anxiety. The PAM tool will provide a measurement of
empowerment and be used to evaluate the degree to
which patients feel that they are in control of their
health status. Changes in analgesic and drug require-
ment will be a secondary effectiveness outcome. An eco-
nomic evaluation will also be undertaken as a secondary
outcome measure.
Intervention
The intervention comprises a total of six consecutive
once-weekly cognitive behavioural therapy sessions
delivered to small groups (5-8) of men with CP/CPPS.
Each session will last 2 hours and will be led by a Con-
sultant Clinical Psychologist with support from a Specia-
list Pain Nurse. There will be further input from a
Consultant Pain Specialist and Senior Urologist if
required particularly in the initial sessions. The sessions
will focus on re-enablement through patient education,
identifying and challenging negative thoughts, fostering
a sense of control and introducing problem-solving and
goal-setting strategies. The content of each session is
briefly detailed in Table 2.
All patients randomised to the intervention arm will
be able to leave the study at any time and all will be
offered standard pain clinic care thereafter. We will
carry out both intention to treat and per protocol
analysis.
Data Collection, Management and Analysis
Data will be collected and managed by a Specialist
Research Nurse. The Specialist Research Nurse will be
responsible for the day-to-day running of the trial as
well as the collection of all administrative, demographic
and outcome data. She will be the key contact for parti-
cipants requiring support or advice throughout the
study.
O u t c o m ed a t aw i l lb ec o l l e c t e da tt h et i m eo fe n r o l -
ment into the study and again at 2, 6 and 12 months
reviews after the commencement of treatment as part of
a routine outpatient pain clinic review. The Specialist
Research Nurse responsible for collecting these data will
not be aware which treatment each patient has received.
Statistical analysis
First descriptive and demographic statistics will be pre-
sented at baseline and follow-up measurements includ-
ing measures of locations, for example mean or median
and measures of spread including standard deviations or
interquartile range depending on the distribution of
measurements. Further, percentages and the 95% confi-
dence intervals will be given for categorical data strati-
fied by treatment group. All statistical tests will be
carried out using two-sided tests at 5% significance level.
Given the repeated nature of our study, we will use
the analysis of covariance approach recommended by
Table 2 Group-directed CBT health improvement intervention
Content Aim
Week 1 Introduction to programme. Ice-breaking exercise Information on CPPS
(Consultant Pain Specialist) Set goals
Facilitate group to bond. Validates pain experience Promote
re-engagement with valued activities
Week 2 Education re Gate Control Theory Identify gate openers Review goals
Homework re goals Homework re gate closers
Validate pain experience Foster a sense of some control
Increase valued activities/quality of life
Week 3 Education re Hot Cross Bun (CBT) Introduce Thought Records Homework:
complete Thought Records
Introduce cognitive behavioural Principles Begin to identify
automatic thoughts
Week 4 Thought Records Homework: complete Thought Records Identify automatic thoughts and unhelpful behavioural
response. Link to emotional state
Week 5 Challenging Thoughts Homework: Thought Challenging Challenge unhelpful thoughts. Identify more appropriate
thoughts Problem-solving strategies
Week 6 Communication Skills Problems solving strategies Identify and reduce solicitous
behaviour
A programme of group-directed cognitive behavioural therapy designed specifically for men with CP/CPPS.
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ments are analysed at each follow-up time point adjust-
ing for baseline and other confounding factors [9].
Study Administration and Ethical Issues
Access to patient data will be restricted to the Specialist
Research Nurse and all members of the NNUH CP/
CPPS Research Group (see Table 3). All data will be
anonymised. Paper records will be stored in locked filing
cabinets and electronic data will be held on password-
protected NHS computers.
The Public and Patient Involvement in Research
(PPIRes) department at NHS Norfolk has been con-
sulted in the development of this trial. Furthermore, a
patient with CP/CPPS has been invited to steering
group meetings and has been involved with the study
design and development.
The Norfolk and Norwich University Hospital NHS
Foundation Trust will be the lead sponsor for this study.
Funding for the trial has been obtained through the
NHS East of England Regional Innovation Fund.
The NHS Indemnity Scheme will meet the potential
legal liability of the Norfolk and Norwich University
Hospital NHS Foundation Trust for harm to partici-
pants in the conduct of the study.
Resource Requirements
This study will require additional resources from the
Norfolk and Norwich University Hospital NHS Founda-
tion Trust. These include the involvement of a number
of health care professionals in the provision of the
healthcare intervention. A Specialist Research Nurse will
also be required to co-ordinate the study and to collect
data on effectiveness outcomes. Funding will be required
for room hire and refreshments for the participants.
Administrative expenses and licence fees for the vali-
dated instruments to assess outcomes constitute further
costs.
These costs will be met entirely through funding from
the NHS East of England Regional Innovation Fund (see
Table 4).
Study Plan
Week 1:
Initial visit, enrolment, consent, baseline NIH-CPSI/
SF36/HAD/PAM
Pain Management Centre.
Duration - approximately 20 minutes
Table 3 NNUH CP/CPPS Research Group
Mr Mark Rochester MA MB BChir MD MRCS(Eng) FRCS(Urol)
Consultant Urological Surgeon
Norfolk and Norwich University Hospitals NHS Foundation Trust
Colney Lane
Norwich, NR4 7UY
Mr James Armitage MBBS BSc(Hons) MD MRCS(Eng) FRCS(Urol)
Specialist Registrar in Urology
Norfolk and Norwich University Hospitals NHS Foundation Trust
Colney Lane
Norwich, NR4 7UY
Dr Mark Sanders MD FRCA
Consultant Anaesthetist
Norfolk and Norwich University Hospitals NHS Foundation Trust
Colney Lane
Norwich, NR4 7UY
Dr Paula Christmas
Consultant Clinical Psychologist
Pain Management Centre
Norfolk and Norwich University Hospitals NHS Foundation Trust
Norwich Community Hospital Site
Bowthorpe Road
Norwich, NR2 3TU
A list of all members of the Norfolk and Norwich University Hospitals CP/CPPS
Research Group.
Table 4 Breakdown of study costs
Staff Involvement
Urology Research Nurse, Band 6(30), 1.0WTE
£42,551
Pain Specialist Nurse, Band 6(30), 0.4WTE
£17,021
CBT-trained Clinical Psychologist, Band 8C, 0.2WTE
£16,706
Admin Assistant, Band 3(12) 0.4WTE
£9,246
Medical Statistician, Band 7 - based on PM, 5%
£2,499
Consultant Input, 120 hours - 1 hour per participant £111.14
£13,337
SpR input - 120 hours, 1 hour per participant £39.65
£4,758
Departmental Costs
Room Hire for therapy sessions - 2 hourly sessions, 10 individual groups,
1
session per week for 8 weeks per group. (60 participants) £15.91per
hour
(£2,546)
Refreshments for group sessions (60 participants) £40.00 per patient
(£2,400)
Research Assessment Room Hire: 4 appointments × 45 mins for 120
participants £15.91 per hour
(£5,728)
Direct Patient Costs
Consumable costs for study - stationary, postage, telephone £20.00 per
patient
(£2,400)
Other Costs
R&D Sponsorship Costs
£1,875
SF-36 and HADS Questionnaire Licence costs
£3,200
ISR CTN Registration
£200
TOTAL RESEARCH COSTS
£124,466
A comprehensive listing of all of the research costs associated with the
SMART-P randomised controlled trial.
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Therapeutic intervention as in Table 2
Pain Management Centre
Duration - approximately 120 minutes per session
Also at the conclusion of week 7, NIH-CPSI/SF36/
HAD/PAM
Week 9-10:
Telephone follow-up with key contact to maintain
engagement in both study arms and address concerns
that may arise.
Week 31:
Six month follow-up assessment, NIH-CPSI/SF36/
HAD/PAM
Pain Management Centre
Duration - approximately 20 minutes (Option of tele-
phone or email follow-up depending on patient
preference)
Week 33-34:
Telephone follow-up with key contact to maintain
engagement in both study arms and address concerns.
Week 57:
Final follow-up assessment, NIH-CPSI/SF36/HAD/
PAM
Pain Management Centre
Duration - approximately 20 minutes
Dissemination and Outcome
All study participants will be contacted in writing to
thank them for participating and to provide them with
either a brief synopsis of the study findings and the
implications for future practice or a full report depend-
ing on participant preference.
We intend to present the findings of the study at
national and international urological meetings (for
example, the annual meetings of the British, European
and American Urological Asssociations). We also plan
to publish the study findings in high impact peer
reviewed medical journals.
We believe that the group-directed self management
programme will be a more effective treatment for men
with CP/CPPS than standard treatment. If this is
demonstrated to be the case in this study it will have
profound implications for the future care of this group
of patients. We anticipate that group-directed self man-
agement may then become the new international stan-
dard of care for patients with CP/CPPS.
Acknowledgements
We are grateful to Helen Green, Specialist Research Nurse at Norfolk and
Norwich University Hospital, for her help with enrolling patients and the
day-to-day running of the study. We also thank Dr John Keep for his
valuable contribution to the trial design.
Author details
1Norfolk and Norwich University Hospital NHS Foundation Trust Colney Lane
Norwich, NR4 7UY, UK.
2Pain Management Centre Norfolk and Norwich
University Hospital NHS Foundation Trust Norwich Community Hospital Site
Bowthorpe Road Norwich, NR2 3TU, UK.
Authors’ contributions
MR and JA conceived the study, obtained funding and wrote the study
protocol. PC and MS were responsible for developing the cognitive
behavioural therapy sessions. All authors contributed to the study design
and approved the final version of the manuscript for publication.
Competing interests
The authors declare that they have no competing interests.
Received: 4 July 2011 Accepted: 26 September 2011
Published: 26 September 2011
References
1. McNaughton-Collins M, Stafford RS, O’Leary MP, Barry MJ: How common is
prostatitis? A national survey of physician visits. J Urol 1998,
159:1224-1228.
2. Habermacher GM, Chason JT, Schaeffer AJ: Prostatitis/chronic pelvic pain
syndrome. Annu Rev Med 2006, 57:195-206.
3. Keltikangas-Jarvinen L, Ruokalainen J, Lethonen T: Personality pathology
underlying chronic prostatitis. Psychother Psychosomat 1982, 37:87-95.
4. Nickel JC, Mullins C, Tripp DA: Development of an evidence-based
cognitive behavioral treatment program for men with chronic
prostatitis/chronic pelvic pain syndrome. World J Urol 2008, 26(2):167-72.
5. Tripp DA, Nickel JC, Landis JR: Predictors of quality of life and pain in
chronic prostatitis/chronic pelvic pain syndrome: Findings from the
Table 5
Month
1234567891 01 11 21 31 41 51 6
Ethics Approval
Establish steering committee
Recruit new staff
First consultations with patients begin
Group therapy sessions commence
Recruiting 10-12 patients per month
Review first patients’ progress
Initial data analysis
Presentation of data at urology meeting
Rochester et al. Trials 2011, 12:210
http://www.trialsjournal.com/content/12/1/210
Page 6 of 7National Institutes of Health Chronic Prostatitis Cohort Study. BJU Int
2004, 94:1279-1282.
6. Department of Health: Improving the health and well-being of people
with long term conditions. [http://www.dh.gov.uk/prod_consum_dh/
groups/dh_digitalassets/@dh/@en/@ps/documents/digitalasset/dh_111187.
pdf].
7. Brown CT, Yap T, Cromwell DA, Rixon L, Steed L, Mulligan K, Mundy A,
Newman SP, van der Meulen J, Emberton M: Self management for men
with lower urinary tract symptoms: randomised controlled trial. BMJ
2007, 334(7583):25-28.
8. Litwin MS, McNaughton-Collins M, Fowler FJ Jr, Nickel JC, Calhoun EA,
Pontari MA, Alexander RB, Farrar JT, O’Leary MP: The National Institutes of
Health chronic prostatitis symptom index: development and validation
of a new outcome measure. J Urol 1999, 162(2):369-375.
9. Frison L, Pocock SJ: Repeated measures in clinical trials: analysis using
mean using mean summary statistics and its implications for design.
Stat Med 1992, 11(13):1685-1704.
doi:10.1186/1745-6215-12-210
Cite this article as: Rochester et al.: Self Management Activation
Randomised Trial for Prostatitis (SMART-P): study protocol for a
randomised controlled trial. Trials 2011 12:210.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Rochester et al. Trials 2011, 12:210
http://www.trialsjournal.com/content/12/1/210
Page 7 of 7